Autosomal Dominant Polycystic Kidney Disease: 2009 Update for Internists
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Because autosomal dominant polycystic kidney disease (ADPKD) is one of the most common genetic abnormalities seen in today’s medical practice, many internists will likely treat patients affected by this condition. Genetic abnormalities have been increasingly recognized, and the pathophysiology of the disease is beginning to be unraveled. Because of advances in imaging technology, surrogate markers for disease progression have allowed clinical studies of newer therapeutic agents to proceed. In the near future, therapies for this common genetic disease may be available to either prevent or stabilize the disease course for many affected individuals.
Abstract
Because autosomal dominant polycystic kidney disease (ADPKD) is one of the most common genetic abnormalities seen in today’s medical practice, many internists will likely treat patients affected by this condition. Genetic abnormalities have been increasingly recognized, and the pathophysiology of the disease is beginning to be unraveled. Because of advances in imaging technology, surrogate markers for disease progression have allowed clinical studies of newer therapeutic agents to proceed. In the near future, therapies for this common genetic disease may be available to either prevent or stabilize the disease course for many affected individuals.
참고문헌 (19)
- Rossetti S, "Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease", J Am Soc Nephrol, 18, pp.2143~2160 (2007)
- Rossetti S, "Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease", Kidney Int, 75, pp.848~855 (2009)
- Torra R, "Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2", J Am Soc Nephrol, 7, pp.2142~2151 (1996)
- Harris PC, "Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease", J Am Soc Nephrol, 17, pp.3013~3019 (2006)
- Pei Y, "A “two-hit” model of cystogenesis in autosomal dominant polycystic kidney disease?", Trends Mol Med, 7, pp.151~156 (2001)
- Nauli S, "Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells", Nat Genet, 33, pp.129~137 (2003)
- Patel V, "Advances in the pathogenesis and treatment of polycystic kidney disease", Curr Opin Nephrol Hypertens, 18, pp.99~106 (2009)
- Grantham JJ, "Volume progression in polycystic kidney disease", N Engl J Med, 354, pp.2122~2130 (2006)
- Grantham JJ, "Determinants of renal volume in autosomal-dominant polycystic kidney disease", Kidney Int, 73, pp.108~116 (2008)
- Pei Y, "Unified criteria for ultrasonographic diagnosis of ADPKD", J Am Soc Nephrol, 20, pp.205~212 (2009)
- Huang E, "DNA testing for live kidney donors at risk for autosomal dominant polycystic kidney disease", Transplantation, 87, pp.133~137 (2009)
- Ecder T, "Cardiovascular abnormalities in autosomaldominant polycystic kidney disease", Nat Rev Nephrol, 5, pp.221~228 (2009)
- Steinman TI, "Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease", Nephrol Dial Transplant, 23, pp.431~433 (2008)
- Grantham JJ, "Clinical practice: autosomal dominant polycystic kidney disease", N Engl J Med, 359, pp.1477~1485 (2008)
- Elzinga LW, "Trimethoprim-sulfamethoxazole in cyst fluid from autosomal dominant polycystic kidneys", Kidney Int, 32, pp.884~888 (1987)
- Elzinga LW, "Ciprofloxacin activity in cyst fluid from polycystic kidneys", Antimicrob Agents Chemother, 32, pp.844~847 (1988)
- Wilson PD, "Polycystic kidney disease", N Engl J Med, 350, pp.151~164 (2004)
- Torres VE, "Autosomal dominant polycystic kidney disease", Lancet, 369, pp.1287~1301 (2007)
- Chapman AB, "Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies", Clin J Am Soc Nephrol, 3, pp.1197~1204 (2008)